^
No biomarker
SCCHN
cisplatin + 5-fluorouracil + docetaxel
Sensitive
:
A1
No biomarker
SCCHN
nivolumab
Sensitive
:
A1
No biomarker
SCCHN
TPF
Sensitive
:
A1
PD-L1 expression
SCCHN
pembrolizumab
Sensitive
:
A1
No biomarker
SCCHN
cetuximab
Sensitive
:
A1
No biomarker
SCCHN
pembrolizumab
Sensitive
:
A1
PD-L1 expression
SCCHN
pembrolizumab
Sensitive
:
A1
No biomarker
SCCHN
methotrexate
Sensitive
:
A2
PD-L1 negative
SCCHN
methotrexate
Sensitive
:
A2
PD-L1 negative
SCCHN
TPeX
Sensitive
:
A2
PD-L1 negative
SCCHN
pembrolizumab
Sensitive
:
A2
PD-L1 negative
SCCHN
cetuximab
Sensitive
:
A2
PD-L1 negative
SCCHN
5-fluorouracil
Sensitive
:
A2
PD-L1 expression
SCCHN
ADX-2191
Sensitive
:
A2
PD-L1 expression
SCCHN
cetuximab
Sensitive
:
A2
PD-L1 expression
SCCHN
5-fluorouracil
Sensitive
:
A2
No biomarker
SCCHN
TPeX
Sensitive
:
A2
No biomarker
SCCHN
cisplatin
Sensitive
:
A2
No biomarker
SCCHN
5-fluorouracil
Sensitive
:
A2
No biomarker
SCCHN
pembrolizumab + nivolumab
Sensitive
:
A2
No biomarker
SCCHN
AT-406
Sensitive
:
B
CDKN2A negative
SCCHN
panitumumab
Sensitive
:
B
HRAS mutation
SCCHN
tipifarnib
Sensitive
:
B
TMB-H
SCCHN
durvalumab
Sensitive
:
B
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our